Neuroendocrine Tumor Treatment Market Size Report, 2032

Neuroendocrine Tumor (NET) Treatment Market – By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy), Indication (Lungs NET, Pancreatic NET, Gastrointestinal NET), Route of Administration (Oral, Parenteral), End-use, & Global Forecast 2024 – 2032 

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing incidence of neuroendocrine tumors

3.2.1.2&nbsp;&nbsp;&nbsp; Development of new treatments

3.2.1.3&nbsp;&nbsp;&nbsp; Supportive government policies, grants, and funding for research in oncology

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of development

3.2.2.2&nbsp;&nbsp;&nbsp; Lack of awareness among the people

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Pipeline analysis

3.6&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Therapy, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Somatostatin analogs (SSAs)

5.3&nbsp;&nbsp;&nbsp; Targeted therapy

5.4&nbsp;&nbsp;&nbsp; Chemotherapy

5.5&nbsp;&nbsp;&nbsp; Other therapies

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Indication, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Lungs NET

6.3&nbsp;&nbsp;&nbsp; Pancreatic NET

6.4&nbsp;&nbsp;&nbsp; Gastrointestinal NET

6.5&nbsp;&nbsp;&nbsp; Other indications

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Oral

7.3&nbsp;&nbsp;&nbsp; Parenteral

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-Use, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospitals &amp; clinics

8.3&nbsp;&nbsp;&nbsp; Cancer treatment centers

8.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Netherlands

9.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

9.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; AVEO Pharmaceuticals, Inc.

10.2&nbsp;&nbsp;&nbsp; Boehringer Ingelheim International GmbH

10.3&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb

10.4&nbsp;&nbsp;&nbsp; Eli Lilly &amp; Company

10.5&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

10.6&nbsp;&nbsp;&nbsp; Hutchison MediPharma Limited

10.7&nbsp;&nbsp;&nbsp; Ipsen

10.8&nbsp;&nbsp;&nbsp; Jubilant Life Sciences Ltd.

10.9&nbsp;&nbsp;&nbsp; Lantheus Holdings, Inc. (Progenics Pharmaceuticals)

10.10&nbsp;&nbsp;&nbsp; Novartis AG

10.11&nbsp;&nbsp;&nbsp; Pfizer Inc.

10.12&nbsp;&nbsp;&nbsp; Tarveda Therapeutics 
&nbsp;

Neuroendocrine Tumor NET Treatment Market

Get a free sample of this report